Posted: October 12th, 2022

Psychotropic medication agent (lurasidone)

Create a research information on your assigned psychotropic medication agent (lurasidone). Your research information must be within the type of a top level view with references, and it is best to incorporate visible components reminiscent of idea maps, charts, diagrams, photos, coloration coding, mnemonics, and/or flashcards. Be inventive! It shouldn’t be within the format of an APA paper. Make a research information for the psychotropic medication agent you’ve got been assigned (lurasidone). Your research information must be within the type of a top level view with references, and visible components reminiscent of idea maps, charts, diagrams, photos, coloration coding, mnemonics, and/or flashcards must be included. Be creative! It shouldn’t be formatted within the method of an APA paper. Your information must be knowledgeable by the FDA-approved and Evidenced-Primarily based, Medical Follow Pointers Analysis but in addition supported by at the very least three different scholarly assets.
Areas of significance it is best to handle, however usually are not restricted to, are:
Title web page
Description of the Psychopharmacological medication agent together with model and generic names and acceptable FDA indication makes use of
Any supporting, legitimate and dependable analysis for non-FDA makes use of
Drug classification
The medication mechanism of motion
The medication pharmacokinetics
The medication pharmacodynamics
Mechanism of Motion
Applicable dosing, administration route, and any issues for dosing alterations
Concerns of use and dosing in particular specialty populations to contemplate youngsters, adolescents, aged, being pregnant, suicidal behaviors, and so on.
Definition of Half-life, why half-life is essential, and the half-life on your assigned medication
Unintended effects/hostile response potentials
Contraindications to be used together with important drug to drug interactions
Overdose Concerns
Diagnostics and labs monitoring
Comorbidities issues
Authorized and moral issues
Pertinent affected person schooling issues
Reference PageRequired Readings Freudenreich, O., Goff, D. C., & Henderson, D. C. (2016). Antipsychotic medicine. In T. A. Stern, M. Favo, T. E. Wilens, & J. F. Rosenbaum. (Eds.), Massachusetts Common Hospital psychopharmacology and neurotherapeutics (pp. 72–85). Elsevier. American Psychiatric Affiliation. (2019). Follow guideline for the therapy of sufferers with schizophrenia. https://www.psychiatry.org/File%20Library/Psychiat… cal%20Follow%20Pointers/APA-Draft-Schizophrenia-TreatmentGuideline.pdfClozapine REMS. (2015). Clozapine REMS: The only shared system for clozapine. https://www.clozapinerems.com/CpmgClozapineUI/rems/pdf/useful resource s/Clozapine_REMS_A_Guide_for_Healthcare_Providers.pdfFunk, M. C., Seashore, S. R., Bostwick, J. R., Celano, C. M., Hasnain, M., Pandurangi, A., Khandai, A., Taylor, A., Levenson, J. L., Riba, M., & Kovacs, R. J. (2018). Useful resource doc on QTc prolongation and psychotropic drugs. American Psychiatric Affiliation. https://www.psychiatry.org/File%20Library/Psychiatrists/Directories/Li brary-and-Archive/resource_documents/Useful resource-Doc-2018- QTc-Prolongation-and-Psychotropic-Med.pdfKay, S. R., Fiszbein, A., & Opler, L. A. (1987). The Constructive and Damaging Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2), 261–276. https://doi.org/10.1093/schbul/13.2.261Levenson, J. C., Kay, D. B., & Buysse, D. J. (2015). The pathophysiology of insomnia. Chest, 147(four), 1179–1192. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4388122/McClellan, J. & Inventory. S. (2013). Follow parameter for the Assessment and therapy of youngsters and adolescents with schizophrenia. Journal of the American Academy of Youngster and Adolescent Psychiatry, 52(9), 976–990. https://www.jaacap.org/article/S0890-8567(09)62600-9/pdfNaber, D., & Lambert, M. (2009). The CATIE and CUtLASS research in schizophrenia: Outcomes and implications for clinicians. CNS Medication, 23(eight), 649–659. https://doi.org/10.2165/00023210-200923080-00002Medication Assets U.S. Meals & Drug Administration. (n.d.). Medication@FDA: FDA-approved medicine. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm

Order | Check Discount

Tags: Psychotropic medication agent (lurasidone)